Group 1: Retail Industry Overview - The retail industry is focusing on three main investment themes for the second half of 2025: strong product momentum, improved operational conditions, and large comprehensive enterprises [7] - The beauty and personal care sector is showing strong performance, with a year-on-year growth of 62.51% in Q1 2025 for companies like Jinbo Biological and 28.01% for Marubi Biological [38] - The jewelry sector is witnessing a shift towards lighter and more affordable gold products, driven by younger consumers and the trend of diversification in the market [7] Group 2: Consumer Confidence and Sales Performance - In the first quarter of 2025, the total retail sales of consumer goods reached 12.47 trillion yuan, with a year-on-year increase of 3.6% [14] - The consumer confidence index showed a recovery trend in early 2025, indicating a positive outlook for retail consumption [14] - The beauty and jewelry categories experienced year-on-year retail sales growth of 5.48% and 8.06% respectively in the same period [14] Group 3: E-commerce and Offline Trends - E-commerce sales showed a mixed performance, with a total sales index of 50.6% in May 2025, reflecting a slight decline compared to previous months [23] - The offline retail market is stabilizing, with a noticeable recovery in shop rental rates, which reached 53.6% in April and May 2025 [29] - The operating space index showed fluctuations but remained stable, indicating a cautious approach to new store openings [29] Group 4: Investment Recommendations - The report recommends focusing on companies with strong product momentum and operational improvements, such as Proya, Giant Biological, and Marubi Biological [62] - The beauty sector is highlighted for its resilience and growth potential, with specific companies recommended for investment based on their strong performance metrics [62] - The medical beauty sector is also emphasized, particularly companies that are expanding their product lines and improving operational capabilities [7][63]

Investment Rating - The industry investment rating is "Positive" [6] Core Viewpoints - In May 2025, the total retail sales of consumer goods increased by 6.4% year-on-year, with a month-on-month acceleration primarily due to the early timing of the "6·18" promotional event [1] - Essential consumption categories showed steady growth, while discretionary categories continued to recover, with significant increases in sales for home appliances and furniture driven by government policies [2][3] - Online retail channels experienced robust growth, while offline channels showed structural differentiation, with a continued preference for high-cost performance products among consumers [4] Summary by Sections Retail Sales Performance - In May 2025, the total retail sales of consumer goods reached a year-on-year growth of 6.4%, with a month-on-month increase of 1.3 percentage points compared to April [1] - Cumulative retail sales from January to May 2025 showed a year-on-year growth of 5.0%, indicating a steady recovery in consumption [1] Consumption Types - Essential consumption maintained steady growth, with food, beverages, and daily necessities showing year-on-year sales increases of 14.6%, 0.1%, and 8.0% respectively [2] - Discretionary consumption categories, such as cosmetics and apparel, showed signs of recovery, with notable performance in gold and jewelry sales due to rising gold prices [2][3] Policy Impact - High-growth categories benefited from supportive consumption policies, with home appliances sales increasing by 53.0% year-on-year, furniture by 25.6%, and gold and silver jewelry by 21.8% [3] - The impact of government subsidies on consumer purchases was significant, particularly in the home improvement sector [3] Retail Channel Dynamics - Online retail sales grew by 8.5% year-on-year in the first five months of 2025, with physical goods online retail accounting for 24.5% of total retail sales [4] - Offline retail channels showed a mixed performance, with convenience stores and specialty stores growing at 8.5% and 6.3% respectively, while department stores lagged behind [4] Investment Strategy - The report suggests focusing on durable goods sectors benefiting from policy support and companies with strong channel integration and product competitiveness [4]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry index decreased by 1.49% in the week of June 9 to June 13, 2025, underperforming the Shanghai Composite Index by 1.24 percentage points [6][13] - The jewelry sector showed the highest growth among retail sub-sectors, with a weekly increase of 4.99% and a year-to-date increase of 37.10% [17][20] - The opening of the POPOP store by Pop Mart in Shanghai represents a strategic expansion into the jewelry market, leveraging popular IPs to attract young consumers [25][26] Summary by Sections Retail Market Review - The retail industry index closed at 2120.43 points, down 1.49% for the week, and down 5.29% year-to-date [6][13] - Among 31 primary industries, the retail sector ranked 25th in performance [14][16] POPOP Store Opening - Pop Mart's POPOP store features products based on popular IPs, targeting young consumers with a price range of 400 to 3000 yuan [25][26] - The store aims to resonate emotionally with consumers, highlighting the importance of jewelry as a cultural and emotional symbol for the youth [26][29] Investment Recommendations - Investment focus on high-quality companies in high-growth sectors driven by emotional consumption themes [7] - Key recommendations include: - Gold and jewelry brands with differentiated product offerings: Old Paved Gold, Chao Hong Ji, and Zhou Da Sheng [31] - Retail companies adapting to trends: Yonghui Supermarket and Aiying Room [31] - High-quality domestic beauty brands: Maogeping, Proya, and Shangmei [32] - Medical beauty product manufacturers: Aimeike and Kedi-B [32] Company-Specific Insights - Old Paved Gold achieved a revenue of 8.506 billion yuan in FY2024, a 167.5% increase, with a net profit of 1.473 billion yuan, up 253.9% [33] - Chao Hong Ji reported a revenue of 6.518 billion yuan in 2024, a 10.5% increase, with a net profit of 194 million yuan, down 41.9% [39] - Zhou Da Sheng's revenue for 2024 was 13.891 billion yuan, down 14.7%, with a net profit of 1.010 billion yuan, down 23.2% [43]

一、股份减持计划实施情况 1、减持股份来源 证券代码：300896 证券简称：爱美客 公告编号：2025-023 号 爱美客技术发展股份有限公司 关于公司董事股份减持计划期限届满暨实施完成的公告 公司董事王兰柱保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 爱美客技术发展股份有限公司（以下简称"公司"或"本公司"）于2025 年2月23日披露了《关于公司董事减持股份预披露公告》（公告编号：2025-002）。 持有公司股份9,216,861股（占公告当日公司扣除回购股数后总股本比例的3.06%） 的董事王兰柱先生计划在本公告披露之日起15个交易日后的3个月内以集中竞价 方式，减持本公司股份不超过2,298,526股（即不超过公告当日公司扣除回购股 数后总股本比例的0.76%）。 公司于2025年6月16日收到董事王兰柱先生发来的《关于股份减持计划实施 情况的告知函》，截至2025年6月16日收市，上述股份减持计划实施期限已届满。 王兰柱先生在减持计划期间未减持其所持有的公司股份，本次减持计划中尚未实 施的减 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [29]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 5.06% from May 30, 2025, to June 12, 2025, exceeding the CSI 300 index by approximately 4.19 percentage points [10][24]. - Most sub-sectors within the industry recorded positive returns during the same period, with other biological products and raw materials leading with increases of 6.57% and 4.92%, respectively [11][24]. - Approximately 83% of stocks in the industry achieved positive returns, with notable performers such as Yiming Pharmaceutical rising by 94.83% [12][15]. - The overall industry valuation has increased, with the SW pharmaceutical and biotechnology industry index's PE (TTM) at approximately 50.45 times, which is relatively low compared to historical levels [16][24]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 5.06% from May 30, 2025, to June 12, 2025 [10]. - Most sub-sectors recorded positive returns, with significant gains in other biological products and raw materials [11]. - About 83% of stocks in the industry posted positive returns, with Yiming Pharmaceutical showing the highest increase [12][15]. 2. Industry News - The National Medical Insurance Administration announced that Hunan Province completed its annual medical insurance fund settlement ahead of schedule, distributing 9.22 billion yuan to 31,000 medical institutions [22]. - The report highlights the ongoing positive developments in the innovative drug sector, including a significant collaboration between Sanofi and Pfizer worth 6 billion USD [26]. 3. Company Announcements - Chengdu Kanghong Pharmaceutical Group's subsidiary received approval for a clinical trial of a new drug, which is expected to enhance its market competitiveness [23]. 4. Industry Outlook - The report suggests continued focus on investment opportunities within the innovative drug supply chain and related sectors, including medical devices and traditional Chinese medicine [26].

Core Viewpoint - The botulinum toxin industry in China is experiencing rapid growth, with the market size projected to increase from 1.9 billion yuan in 2017 to 9.9 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 26.6% [1][13]. Industry Overview - Botulinum toxin, originally used for treating muscle spasms, has become a popular choice in medical aesthetics due to its minimal invasiveness and quick recovery time [3][13]. - The application range of botulinum toxin is expanding beyond traditional uses like wrinkle reduction and facial slimming to include treatments for conditions such as migraines and muscle tension disorders [1][13]. Market Dynamics - The medical aesthetics market in China is projected to reach 288 billion yuan by 2024, with a year-on-year increase of 8.03%, indicating a growing consumer demand for beauty enhancement services [11][13]. - The market is characterized by a "six-way split" among leading products, with brands like Botox, Hengli, and Letyb gaining significant market shares [15][17]. Competitive Landscape - The botulinum toxin market is competitive, with established companies like Fosun Pharma, Haohai Biological Technology, and Lanzhou Biological Products Research Institute leading the industry [17][18]. - New entrants are emerging, leveraging innovative technologies and marketing strategies to capture market share [17]. Development Trends 1. **Increasing Industry Penetration** - As living standards rise, the penetration rate of medical aesthetics is expected to increase, particularly in lower-tier cities and rural areas, driven by a younger consumer base [23]. 2. **Enhanced Regulatory Oversight** - The government is intensifying regulations on botulinum toxin production and distribution to ensure safety and quality, which will promote the healthy development of the market [24]. 3. **Rise of Recombinant Botulinum Toxin** - Recombinant botulinum toxin is anticipated to become a future trend due to its lower biological risks, higher purity, and production efficiency, addressing limitations of traditional products [25].

Group 1 - Medical device sector shows strong performance with ETF fund (159797) experiencing significant trading volume and net inflow of funds [1] - Recent policy document issued on June 9 aims to improve healthcare resources and insurance mechanisms, which is seen as a major driver for pharmaceutical companies [3] - Citic Securities predicts a trend of low-to-high earnings growth in the medical device sector, with significant improvements expected in the second half of the year [4] Group 2 - Structural investment opportunities exist within the medical device sector, with certain companies expected to achieve high growth in Q2 and Q3 [5] - The easing of US-China tariffs is beneficial for medical device companies, potentially lowering production costs and expanding overseas market share [6] - The medical device ETF fund (159797) covers core areas such as medical equipment and in vitro diagnostics, with top ten weighted stocks accounting for 46.78% [6][7]

Group 1 - The beauty and personal care sector has shown strong performance in Q1 2025, with the SW Beauty Care Index rising by 13.4%, leading all 31 SW primary industries [4][10][12] - The cosmetics segment is focusing on enhancing brand matrices and introducing new ingredients, benefiting from an optimized competitive landscape [4][6] - The medical beauty market is evolving with new products stimulating consumer interest, and domestic companies are expected to become major competitors in the light medical beauty sector [4][6] Group 2 - The e-commerce sector is witnessing new consumption models and brands, which are helping to drive growth in the industry [4][6] - The report recommends several companies in the cosmetics sector, including Up Beauty and Proya, which have low PE multiples and strong growth potential [4][6] - In the medical beauty segment, companies with high R&D barriers and strong profitability, such as Aimeike, are highlighted as key investment opportunities [4][6] Group 3 - The personal care market is projected to reach CNY 283.3 billion by 2024, with a compound annual growth rate (CAGR) of 8.4% from 2023 to 2028 [32][34] - Domestic brands are increasingly replacing foreign brands in the personal care sector, with a notable rise in innovative products and marketing strategies [32][36] - The high-end market is experiencing significant growth, with premium products seeing a 27% increase in average transaction value in H2 2024 [44]

Core Insights - The medical beauty industry is rapidly emerging, driven by advancements in medical technology and evolving consumer perceptions, expanding from traditional cosmetic surgery to non-invasive beauty treatments, laser skincare, and body management [1][16] - The industry is experiencing significant growth potential due to improved consumer decision-making facilitated by big data, alongside a push towards standardization through enhanced regulation [1][16] - The long-term outlook for the industry remains positive, supported by rising disposable incomes and increasing demand for quality living [1][16] Industry Overview - Medical beauty, abbreviated as "医美," utilizes medical methods, including drugs, instruments, and surgeries, to enhance external beauty and improve physiological functions [2] - The industry encompasses various segments, including facial beauty, body beauty, skin beauty, non-invasive beauty, and oral beauty [2] Market Trends - Consumer acceptance of light medical beauty is increasing, with 34% of consumers planning to engage in light medical beauty services in the coming year, reflecting a 36% year-on-year growth [5] - The emerging consumer base includes young people, men, and consumers from lower-tier markets, indicating a shift in demand driven by changing aesthetic values and rational consumption attitudes [5] Industry Structure - The medical beauty industry chain consists of upstream products and equipment, midstream service providers, and downstream customer acquisition platforms, with a stable upstream structure and a competitive midstream landscape [7][8] - Upstream manufacturers face high entry barriers due to regulatory requirements and technical challenges, making it the most profitable segment of the industry [8] - The downstream market is characterized by intense competition and low concentration, with 71% of service providers being private clinics or beauty salons [10] Market Size and Growth - The Chinese medical beauty market has shown steady growth, with a compound annual growth rate (CAGR) of 17.5% from 2017 to 2021, reaching nearly 190 billion yuan, and is projected to grow at a CAGR of 15.2% to nearly 400 billion yuan by 2026 [11] - The penetration rate of medical beauty services in China was 4.5% in 2022, indicating significant room for growth compared to Japan (11.3%), the U.S. (17.2%), and South Korea (22.0%) [11] Regulatory Environment - The industry has faced challenges such as varying qualifications, false advertising, and price transparency issues, prompting the government to enhance regulatory frameworks and industry standards [14] - Increased compliance awareness among institutions and improved consumer protection mechanisms are expected to foster a healthier development phase for the industry [14] Investment Opportunities - Key companies in the medical beauty sector include Aimeike, Huaxi Biological, Longzi Co., and Huadong Pharmaceutical, which are positioned to benefit from the industry's growth and regulatory improvements [16]

Core Insights - The medical beauty materials market is entering a competitive phase in 2025, with significant approvals for new materials such as agarose and hydroxyapatite, indicating a growing diversity of products [1][10] - The approval of various injection fillers, including recombinant collagen and animal-derived collagen, highlights the rapid development and commercialization of medical beauty materials [1][4] - Investment in medical beauty materials companies has surged, with 12 companies securing funding in the first five months of 2025, reflecting strong interest from investors [4][5] Regulatory Approvals - Hydroxyapatite received two approvals in 2025, with the first compliant product for medical beauty injections approved in February [10] - Agarose also saw its first approval in January 2025, marking a significant milestone for this material in the domestic market [10] - Over 110 products for medical beauty injections have been approved in China, primarily classified as Class III medical devices [2][4] Market Dynamics - The competition for the first regulatory approval (Class III certificate) is intense, as it provides a significant market advantage [10][12] - Companies are increasingly focusing on developing new materials and applications, with many aiming to secure the first approval in various new material categories [11][12] - The market is characterized by a mix of established companies and startups, all vying for a share of the growing medical beauty sector [15][16] Investment Trends - Notable investments in medical beauty materials companies include significant funding rounds for firms like 聚源生物 and 未名拾光, indicating robust investor confidence [5][6] - The trend of startups receiving funding is expected to continue, as the demand for innovative medical beauty solutions grows [4][5] Product Development - Companies are exploring the combination of different materials to enhance product competitiveness, with a focus on safety and efficacy [14][15] - New materials such as PDRN, silk protein, and chitosan are being investigated for their applications in medical beauty and functional skincare [16][17] - The development of multi-indication products is becoming a strategic focus, with companies aiming to address various aesthetic needs [13][15] Future Outlook - The medical beauty market is anticipated to expand, driven by the introduction of new materials and innovative applications [16][17] - The interplay between medical beauty and skincare sectors is expected to create a positive feedback loop, enhancing market growth [16][17] - Ultimately, the success of new materials will depend on their clinical validation and real-world application, as safety and effectiveness remain paramount [16][17]